Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

BACKGROUND: Anti-tumor necrosis factor (anti-TNF) agents are an effective, but costly, treatment for spondyloarthritis (SpA). Worldwide, multiple sets of access criteria aim to restrict anti-TNF therapy to patients with specific clinical characteristics, yet the influence of access criteria on anti-...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cost Eff Resour Alloc
Prif Awduron: Harvard, Stephanie, Guh, Daphne, Bansback, Nick, Richette, Pascal, Saraux, Alain, Fautrel, Bruno, Anis, Aslam
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2017
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5590198/
https://ncbi.nlm.nih.gov/pubmed/28904528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-017-0081-8
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg